Cybin Corp

Cybin Corp is a leading Mushroom Life Sciences Company focused on psychedelic medicines and nutraceutical products. The company currently has two operating divisions: Serenity Life Sciences (Psychedelic Pharmaceutical Products) and Journey (Medicinal Nutraceutical Products).

‍

Request More Information

‍

‍Company Highlights:

• Medical team has run multiple clinical trials and facilitated over $1B in pharma sales.
  
• Top tier clinical advisory team responsible for some of the first published research on microdosing
  
• Clear line of sight to near term revenues through our nutraceutical products.
  
• Strategic partnership and investment in the world's largest psychedelic platform.
  
• Exclusive partnership with the Toronto Centre For Psychedelic Science.
  
• Strong Canadian government relations team made up of former high-level government officials.
  
• Digital team that operates the Journey nutraceutical product line has previously sold over $1B in online products and services.

Team:

Paul Glavine, Co-Founder and CEO

• Serial entrepreneur and investor with vast experience in the biotech and cannabis sectors.
• Co-Founder of Global Canna Brands which was granted the first ever tier 3 cultivation license in Jamaica.
• Sold first cannabis start up TruVerra to Supreme Cannabis Company Inc (TSX Ticker: FIRE).

John Kanakis, Co-Founder and SVP Business Development

• Co-Founder and managing Director of Trinity Venture Partners Inc, a Canadian boutique merchant bank with holdings in the cannabis, technology, consumer packaged goods and pharmaceutical sector.
• Co-Founder of Growpacker Inc, a private contract manufacture of cannabis infused beverages and edibles that operates in California.

Jukka Karjalainen Ph.D., M.D, Chief Medical Officer

• Former Director of medical and regulatory affairs and corporate Vice President at Biovail Pharmaceuticals. Former Medical Director at Eli Lilly and Company (Finland).
  
• Managed multiple corporate Phase 2-3 clinical registration trials and 30 local Phase 3b and 4 trials in over 150 clinical investigator sites.

Rotem Petranker, Clinical Scientific Advisor

• Associate Director and Co-Founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto.
  
• Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing.

Thomas Anderson, Clinical Scientific Advisor

• Research Director and Co-Founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto.
  
• Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing

Summary: Cybin is uniquely positioned as a life science company focused on delivering on both branded, functional mushroom products as well as psychedelic treatments and therapies.

With a proven team of entrepreneurs who have built, scaled and sold businesses, Cybin has attracted top level investment interest. Most recently, they closed on an over subscribed seed round, bringing in over C$3M.

Moving ahead, Cybin looks to establish themselves as one of the most recognizable names in the industry, with a science-informed approach.